Slingshot members are tracking this event:

Novartis' (NVS) FDA Priority Review Expected By May 14th for Midostaurin (PKC412) in Treatment of Acute Myeloid Leukemia (AML) in Newly-Diagnosed Adults with an FMS-Like Tyrosine Kinase-3 (FLT3) Mutation

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks

Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Fda, Priority Review, Midostaurin, Pkc412, Acute Myeloid Leukemia, Flt3 Mutation